Analysis of Physicochemical Properties for Drugs of Natural Origin

被引:56
作者
Camp, David [1 ]
Garavelas, Agatha [2 ]
Campitelli, Marc [3 ]
机构
[1] Griffith Univ, Sch Environm, Nathan, Qld 4111, Australia
[2] Griffith Univ, Eskitis Inst, Nathan, Qld 4111, Australia
[3] QIMR Berghofer Med Res Inst, Herston, Qld 4006, Australia
来源
JOURNAL OF NATURAL PRODUCTS | 2015年 / 78卷 / 06期
关键词
PRODUCT-DERIVED COMPOUNDS; MARKETED ORAL-DRUGS; MEDICINAL CHEMISTRY; CLINICAL-TRIALS; GUIDING PRINCIPLES; DISCOVERY; DESIGN; BIOAVAILABILITY; TRANSPORT; PERSPECTIVE;
D O I
10.1021/acs.jnatprod.5b00255
中图分类号
Q94 [植物学];
学科分类号
071001 [植物学];
摘要
The impact of time, therapy area, and route of administration on 13 physicochemical properties calculated for 664 drugs developed from a natural prototype was investigated. The mean values for the majority of properties sampled over five periods from pre-1900 to 2013 were found to change in a statistically significant manner. In contrast, lipophilicity and aromatic ring count remained relatively constant, suggesting that these parameters are the most important for successful prosecution of a natural product drug discovery program if the route of administration is not focused exclusively on oral availability. An examination by therapy area revealed that anti-infective agents had the most differences in physicochemical property profiles compared with other areas, particularly with respect to lipophilicity. However, when this group was removed, the variation between the mean values for lipophilicity and aromatic ring count across the remaining therapy areas was again found not to change in a meaningful manner, further highlighting the importance of these two parameters. The vast majority of drugs with a natural progenitor were formulated for either oral and/or injectable administration. Injectables were, on average, larger and more polar than drugs developed for oral, topical, and inhalation routes.
引用
收藏
页码:1370 / 1382
页数:13
相关论文
共 71 条
[1]
[Anonymous], 2007, 2007 USP DICT USAN I
[2]
[Anonymous], 2007, PHARM MANUFACTURING
[3]
[Anonymous], 2014, MARTINDALE COMPLETE
[4]
[Anonymous], 2014, CHEMIDPLUS DAT
[5]
[Anonymous], 2015, SCIFINDER
[6]
Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/NCHEM.1243, 10.1038/nchem.1243]
[7]
Natural products to drugs: natural product-derived compounds in clinical trials [J].
Butler, Mark S. .
NATURAL PRODUCT REPORTS, 2008, 25 (03) :475-516
[8]
Natural product and natural product derived drugs in clinical trials [J].
Butler, Mark S. ;
Robertson, Avril A. B. ;
Cooper, Matthew A. .
NATURAL PRODUCT REPORTS, 2014, 31 (11) :1612-1661
[9]
Antibiotics in the clinical pipeline in 2013 [J].
Butler, Mark S. ;
Blaskovich, Mark A. ;
Cooper, Matthew A. .
JOURNAL OF ANTIBIOTICS, 2013, 66 (10) :571-591
[10]
Butler MS, 2005, NAT PROD REP, V22, P162, DOI 10.1039/b402985m